GET THE PREMIUM SUBSCRIPTION FREE FOR 14 DAYS!

CASI Pharmaceuticals Company Profile

9620 Medical Center Drive

Rockville MD 20850

240-864-2600

www.casipharmaceuticals.com

Industry: Biotechnology

Sector: Healthcare


Description

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company’s late-stage clinical drug candidates include , such as MARQIBO, a microtubule inhibitor for the treatment of adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular b-cell non-hodgkin’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE